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Increased expression of the ubiquitin – proteasome pathway in
murine myotubes by proteolysis-inducing factor (PIF) is associated
with activation of the transcription factor NF-kB
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Proteolysis-inducing factor (PIF), isolated from a cachexia-inducing murine tumour, has been shown to stimulate protein breakdown
in C2C12 myotubes. The effect was attenuated by the specific proteasome inhibitor lactacystin and there was an elevation of
proteasome ‘chymotrypsin-like’ enzyme activity and expression of 20S proteasome a-subunits at concentrations of PIF between 2
and 16 nM. Higher concentrations of PIF had no effect. The action of PIF was attenuated by eicosapentaenoic acid (EPA) (50 mM). At a
concentration of 4 nM, PIF induced a transient decrease in IkBa levels after 30min incubation, while no effect was seen at 20 nM PIF.
The level of IkBa, an NF-kB inhibitory protein, returned to normal after 60min. Depletion of IkBa from the cytosol was not seen in
myotubes pretreated with EPA, suggesting that the NF-kB/IkB complex was stabilised. At concentrations between 2 and 8 nM, PIF
stimulated an increased nuclear migration of NF-kB, which was not seen in myotubes pretreated with EPA. The PIF-induced increase
in chymotrypsin-like enzyme activity was also attenuated by the NF-kB inhibitor peptide SN50, suggesting that NF-kB may be
involved in the PIF-induced increase in proteasome expression. The results further suggest that EPA may attenuate protein
degradation induced by PIF, at least partly, by preventing NF-kB accumulation in the nucleus.
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Loss of protein from skeletal muscle is a common phenomenon
associated with a number of catabolic conditions. Of the
proteolytic pathways, the lysosomal (cathepsins) and the cal-
cium-dependent cysteine proteases (calpains) contribute between
15 and 20% of total protein breakdown in muscles (Lecker et al,
1999). Muscle wasting in starvation (Wing and Goldberg, 1993),
sepsis (Tiao et al, 1994), metabolic acidosis (Mitch et al, 1994),
weightlessness (Taillandier et al, 1996), severe trauma (Biolo et al,
2000), denervation atrophy (Medina et al, 1995) and cancer
cachexia, in both mice (Lorite et al, 1998) and humans (Williams
et al, 1999) has been attributed to upregulation of ATP–ubiquitin-
dependent proteolysis (ubiquitin–proteasome). In this process,
proteins are tagged for degradation by the attachment of a
polyubiquitin chain, which is recognised by the 26S proteasome, a
large multisubunit catalytic complex. However, the ubiquitin–
proteasome pathway does not disassemble myofibrils directly and
the calcium–calpain pathway has been suggested to release
myofilaments from the sarcomere before myosin can be degraded
by the proteasome (Hasselgren and Fischer, 2001).
Muscle protein degradation in cancer cachexia appears to be
associated with a sulphated glycoprotein of Mr 24 000 secreted by
cachexia-inducing murine and human tumours (Todorov et al,
1996a; Cabal-Manzano et al, 2001). This substance is capable of
inducing muscle protein breakdown directly, both in vitro and in
vivo (Lorite et al, 1997), and has been named proteolysis-inducing
factor (PIF). PIF has been detected in the urine of weight-losing
patients with carcinoma of the pancreas, breast, ovary, lung, colon,
rectum and liver (Cariuk et al, 1997). Patients with pancreatic
cancer excreting PIF in the urine had a significantly greater total
weight loss and rate of weight loss than patients whose urine did
not contain PIF (Wigmore et al, 2000). Protein degradation
induced by PIF, both in gastrocnemius muscle in vivo and murine
myoblasts in vitro, is associated with increased levels of both
mRNA and protein for the Mr 14 000 ubiquitin conjugating protein
and proteasome a and b subunits (Lorite et al, 2001), suggesting
that the ubiquitin-proteasome proteolytic pathway plays a major
role in the action of PIF. The induction of protein degradation by
PIF has been shown to be completely attenuated by pretreatment
with eicosapentaenoic acid (EPA) (Lorite et al, 1997), which has
been shown to downregulate expression of the key regulatory
components of the ubiquitin–proteasome pathway in skeletal
muscle of mice bearing the MAC16 tumour (Whitehouse et al,
2001a).
Although PIF has been shown to upregulate expression of the
ubiquitin–proteasome proteolytic pathway in murine myotubes
(Gomes-Marcondes et al, 2002), there is no information, to date,
on nuclear transcription factors involved. In primary hepatocytes
and the human cancer cell line Hep G2, PIF has been shown to
activate the transcription factor nuclear factor-kappa B (NF-kB)
resulting in the increased production of interleukin-8 (IL-8),
interleukin-6 (IL-6) and C-reactive protein, and the decreased
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production of transferrin (Watchorn et al, 2001). There was also an
increase in ICAM-1, another NF-kB inducible gene. Protein
degradation induced by TNF-a in murine myotubes also appears
to arise from an increase in ubiquitin-dependent proteolysis (Li
et al, 1998) and studies in transfected cells containing mutant IkBa
proteins insensitive to degradation suggested that NF-kB was an
essential mediator of the TNF-a-induced protein breakdown (Li
and Read, 2000). This suggests that the induction of protein
degradation by PIF may also be mediated through NF-kB. The aim
of the present study was to investigate the effect of PIF on the
activation of NF-kB in C2C12 murine myotubes at concentrations
causing an increased expression of the ubiquitin–proteasome
pathway. Since EPA has been shown to attenuate the catabolic
effect of PIF in murine myoblasts (Smith et al, 1999) the effect of
this essential fatty acid on protein catabolism, activation of the
ubiquitin–proteasome pathway and nuclear accumulation of NF-
kB by PIF has been studied in myotubes to determine potential
mechanisms of signal transduction.
METHODS
Purification of PIF
Pure strain female NMRI mice were obtained from our own
breeding colony and were transplanted with fragments of the MAC
16 tumour into the flank by means of a trocar (Bibby et al, 1987).
MAC16 tumours were originally derived from colon tumours
induced by dimethylhydrazine in NMRI mice (Cowen et al, 1980).
PIF was isolated from tumours that were excised, once weight loss
was established (20–25%). All animal experiments have been
carried out with approval from the British Home Office and the
ethical guidelines followed meet the standards required by the
UKCCR guidelines (Workman et al, 1998). The tumours were
homogenised in 5ml g1 of a Tris buffer (Tris 3.03 g, EGTA
0.4755 g, DTT, 0.3865 g: (PMSF 0.1 M in 12.5ml isopropanol in
2500ml). All reagents were obtained from Sigma-Aldrich, Dorset,
UK unless otherwise stated. After centrifugation (3100 g, 15min),
38% wv1 ammonium sulphate was slowly added to the super-
natant while stirring on ice. The solution was then left stirring
overnight at 41C. Centrifugation at 4000 g for 20min was followed
by ultracentrifugation at 20 000 g for 35min to remove any fat,
after which time the homogenate was dialysed several times in a
10 000MW cutoff ultrafiltration cell against two to three changes of
300ml PBS. The retenate was centrifuged at 4000 g for 20min and
the sample was circulated on an affinity column overnight. The
column itself contains antibodies raised against murine PIF
(Todorov et al, 1996b), which are coupled to protein A on an
Affi-Gel column. PIF was eluted from the column the next day with
0.1 M glycine, pH 2.5, into tubes containing 500 ml Tris pH 8.0. It
was then redialysed in an equal volume PBS and concentrated to
0.5–1.0ml. The purity of PIF was confirmed by polyacrylamide gel
electrophoresis and immunoblotting. This showed a band for PIF
at Mr 24 000, sometimes accompanied by an albumin bound band
at Mr 69 000 (Todorov et al, 1996b). No other bands were apparent.
Cell culture and differentiation of C2C12 myoblasts into
myotubes
All experiments were performed with myotubes since they contain
the myofibrillar proteins actin and myosin seen in skeletal muscle.
C2C12 myoblasts were maintained in a proliferative state of growth
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 5% foetal calf serum and 1% penicillin/streptomycin (Gibco
Life Sciences, UK). For all experimentation, cells were differen-
tiated into myotubes by incubation in DMEM, which had been
supplemented with 2% horse serum and 1% penicillin/streptomy-
cin when the myoblasts became confluent. The medium was
changed every other day and differentiation occurred in 5–7 days.
Measurement of protein degradation
Protein degradation was determined as previously described
(Gomes-Marcondes et al, 2002) in six well multiwell dishes. Just
before the cells were fully differentiated, 20ml of [3H] phenylala-
nine ([3H]-Phe) corresponding to 2 mCi was added to each well and
the cells were incubated at 371C in 5% CO2 overnight in the
absence of any treatment. [3H]-Phe was preprepared by adding
60mg ‘cold’ phenylalanine to 500 ml [3H]-Phe in 4500ml PBS. The
following day (during which time myotubes would have fully
formed), the media was discarded and the cells were rinsed twice
in PBS. DMEM without phenol red (supplemented with 2% horse
serum and 1% penicillin/streptomycin) was added following a 2 h
preincubation, the media was removed and replaced with DMEM
without phenol red (supplemented as previous) along with a range
of concentrations of PIF with or without lactacystin (10 mM) and
2mM ‘cold’ phenylalanine. Cells were then incubated for a further
24 h. Finally, 1ml of supernatant was removed and added to 6ml
optiphase ‘Hi safe 3’ scintillation fluid (Fisher Chemicals, Leicester,
UK). The radioactivity released was analysed using a ‘Tri-carb
2000CA’ liquid scintillation analyser (United Technologies, Pack-
ard, Berks, UK). The data were the same whether expressed as total
[3H]-Phe released or as a percentage of total radioactivity
incorporated.
Measurement of proteasomal ‘chymotrypsin-like’ enzyme
activity in C2C12 myotubes
The ‘chymotrypsin-like enzyme activity of the proteasome was
determined fluorometrically according to the method of Orino et al
(1991). Myotubes were pretreated with EPA for 2 h prior to the
addition of PIF and the EPA remained in the culture medium for
the course of the experiment. After 24 h, myotubes were washed
twice in ice-cold PBS and scraped into approximately 0.5ml
homogenising buffer (20mM Tris, pH7.5, 2mM ATP, 5mM MgCl2,
50mM DTT). Samples were then sonicated for three pulses of 15 s,
with 10 s intervals, with care to avoid heating, and centrifuged at
18 000 g for 10min at 41C to pellet insoluble material. A stock
solution of substrate (10mg N-succinyl-LLVY-7-amido-4-methyl
coumarin in 600 ml dimethyl sulphoxide) was diluted 1 : 1000 in
100mM Tris/HCI, pH 8.0, for use. A volume of 100 ml was added to
50–100 ml of prepared sample. A duplicate set of samples was
included to which the proteasome inhibitor lactacystin (Affiniti
Research Products, Exeter, Devon, UK) had been added to give a
final concentration of 10 mM per well. Samples were then incubated
for 2 h on ice. Fluorescence of the substrate was measured using an
LS50 Luminescence Spectrometer (Perkin-Elmer) at excitation
360 nm and emission 460 nm, and values were adjusted for equal
protein concentrations and for a reaction blank. The substrate
concentration was saturated and the activity was linear with
protein concentration.
Determination of protein concentration
Protein concentrations were determined using a standard com-
mercially available colourimetric protein assay (Biorad, UK)
according to the manufacturer’s instructions.
Western blotting protocol Myoblasts were allowed to differentiate
into myotubes as above, and treated with various concentrations of
PIF as indicated in the figure legends, with or without 2 h
preincubation with 50 mM EPA. The media were rinsed from
myotubes that were homogenised and sonicated in 500–2000 ml
homogenising buffer (as described above). After centrifugation
(18 000 g for 5min) to pellet-insoluble material, the supernatant
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was assayed for protein concentration. Homogenates were
denatured in electrophoresis sample buffer (125mM Tris, pH 6.8,
4% SDS, 10% glycerol, 0.006% bromophenol blue, 2% mercap-
toethanol) by heating to 951C for 5min and electrophoresed on a
12% SDS–polyacrylamide gel (10 cm 10 cm) along with ‘Rain-
bow’ molecular weight markers (Amersham Biosciences, UK).
Proteins were electrotransferred to a nitrocellulose membrane
using an enclosed system for 2 h at a constant voltage of 80V. After
transfer, the membranes were rinsed in wash buffer (0.1% Tween
20 in PBS) and transferred to blocking buffer (5% Marvel in wash
buffer) for 1 h at room temperature. Blots were probed for 20S
proteasome a-subunits, p42 proteasome subunit and inhibitory
protein of NF-kB (IkBa) using appropriate antisera. Primary
antisera were diluted in blocking buffer (Rabbit polyclonal
IkBa1 : 400 Autogen Bioclear, UK anti-p42 1 : 120 and mouse
monoclonal 20Sa 1 : 1500 Affiniti Research Products, Exeter,
Devon, UK) and added to membranes for 1 h at room temperature.
This was followed by washing with 0.1% PBS-Tween for 1 h at
room temperature with agitation, changing the wash buffer every
15–20min. Anti-mouse or anti-rabbit IgG :HRP (horseradish
peroxidase), diluted 1 : 2000 in wash buffer, was added and
incubated for 1 h at room temperature. After incubation with
secondary antibody, the membranes were washed for a further
90min with agitation, again changing the buffer every 15–20min.
Proteins were detected using an ‘Enhanced Chemiluminescence’
(ECL) system (Amersham Biosciences, UK), which is based upon
the oxidation of luminol by HRP, resulting in light emission,
detected by a blue light sensitive autoradiography film. To ensure
equal loading, a parallel gel was stained with 1% Coomassie
Brilliant Blue (in 40% methanol/10% acetic acid) for 1 h.
Electrophoretic mobility shift assay (EMSA) C2C12 myotubes were
treated with EPA and PIF as described in Figure 5A. A vehicle
control (as well as no treatment control) was included, to
differentiate any effects caused by the solvent. The cells were
incubated for 20min with PIF prior to the EMSA assay.
Labelling of consensus oligonucleotides In all, 2 ml NF-kB
(1.75 pmolml1) (Promega UK), oligonucleotide sequence 50-AGT
TGA GGG GAC TTT CCC AGG C-30; 30-TCA ACT CCC CTG AAA
GGG TCC G-50; 1 ml T4 polynucleotide kinase 10 buffer
(Promega, UK); 2 mCi [g-32P]ATP (Amersham Biosciences, UK);
1 ml T4 polynucleotide kinase (Promega, UK) were assembled in a
sterile microcentrifuge tube, the volume was adjusted to 10 ml with
nuclease-free H2O (Promega, UK), and incubated at 371C for 1 h.
The reaction was stopped by the addition of 2 ml 0.5 M EDTA
followed by 88 ml of TE buffer.
Preparation of nuclear proteins The cells were rinsed, scraped
and pelleted in wash buffer (10mM HEPES/KOH pH 7.5, 10mM
KCl, 2mM MgCl2, 1mM DTT, 0.1mM EDTA, 0.4mM PMSF, 0.2mM
NaF, 0.2mM sodium orthovanadate, 0.3mgml1 leupeptin).
Extracts were prepared according to Johnson et al. (1996) with
modifications. The pellets were resuspended in 300 ml of the same
wash buffer and incubated on ice for 15min. In all, 30 ml of 1%
‘Triton X-100’ (octylphenoxy-polyethoxyethanol) was then added
and the cells were lysed by vortexing. A 4-min centrifugation at
2000 g pelleted the nuclei and the supernatant was removed. The
nuclear pellet was resuspended in 50 ml of the ice-cold high-salt
buffer (50mM HEPES, pH 7.8, 50mM KCl, 300mM NaCl, 0.1mM
EDTA, 1mM DTT, 0.4mM PMSF, 0.2mM NaF, 0.2mM sodium
orthovanadate, 10% glycerol) to solubilise nuclear proteins and the
suspension was kept on ice for 20min with a 30 s vortex every 3–
5min. A centrifugation at 15 500 g for 3min yielded the super-
natant containing the protein extract. The concentration of nuclear
extracts was measured by protein assay (as described previously).
Measurements were repeated three times to ensure the accuracy of
the assay.
DNA binding reaction Gel shift binding buffer (2 ml) (Promega,
UK) and nuclear extract (10mg for each test) were added in a
sterile microfuge tube, along with 2 ml unlabelled NFkB (compe-
titor control) or 2 ml of a different unlabelled oligonucleotide
(noncompetitor control). A negative control reaction was also
included, which contained gel shift binding buffer and no sample.
In total, 2 ml of [g-32P] NFkB was then added to tests and controls
and the volumes were equalised with nuclease-free water. The
reactions were then incubated at room temperature for 2 h. Finally,
1 ml of gel loading 10 buffer (250mM Tris-HCI, pH 7.5, 0.2%
bromophenol blue, 40% glycerol) was added to the negative
control, and the reaction products were analysed via electrophor-
esis on an 8% nondenaturing polyacrylamide gel, with a native 5%
polyacrylamide stacking gel, which had been allowed to polymerise
for at least 2 h. The gels were pre-electrophoresed for 10min at
150mV and then electrophoresed (after the addition of samples) at
150mV for approximately 30min, or until the bromophenol blue
dye front reached the base of the gel. The gel was then dried
between Whatman 3MM filter paper and plastic wrap and exposed
to ‘Hyperfilm MP’ for 8–16 h at 701C.
Statistical analysis
Data are expressed as mean7s.e.m. and each experiment was
repeated at least three times. Differences were analysed by two-way
ANOVA followed by Tukey’s post-test. Differences were consid-
ered significant if Po0.05.
RESULTS
In the current experiments, myotubes were used as a model of
skeletal muscle, since they contain the myofibrillar proteins actin
and myosin not found in myoblasts. When C2C12 murine myotubes
labelled with [3H] phenylalanine were treated with PIF for 24 h,
there was an increase in total protein degradation, as evidenced by
increased release of radiolabel (Figure 1). The maximal protein
breakdown was seen at concentrations of PIF between 2 and 16 nM,
with a maximal peak of stimulatory activity (41% increase over
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Figure 1 Effect of PIF in the absence (black boxes) or presence (grey
boxes) of lactacystin (10 mM) on protein degradation in C2C12 myotubes as
determined by [3H] phenylalanine release. Lactacystin was present for 2 h
prior to PIF and was also present throughout the 24 h incubation period. All
values have been normalised to their respective controls and the
experiment was repeated twice, n¼ 3 for each treatment. The data are
expressed as mean7s.e.m. and was measured 24 h after the addition of
PIF. Differences from control are indicated as a, Po0.01 and b, Po0.001,
while differences in the presence of lactacystin are shown as c, Po0.001.
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control) at 4 nM PIF. These concentrations are in the range
expected from maximal tumour release into the circulation (35 nM)
(Todorov et al, 1996a). Protein degradation was attenuated in the
presence of the highly specific and irreversible proteasome
inhibitor lactacystin, which does not inhibit lysosomal protein
degradation (Fenteany and Schreiber, 1998) at a concentration of
10 mM (Figure 1), indicating that the elevated catabolism was due to
increased proteasome activity. There was no effect of lactacystin on
cell viability. Pilot experiments suggested that this concentration
was sufficient to attenuate proteasome activity. PIF induced an
increase in the chymotrypsin-like activity of the proteasome (the
dominant catalytic activity of the b-subunits), with an increase of
more than 10-fold in the presence of 4 nM PIF (Figure 2). The effect
was completely abolished in the presence of lactacystin, confirm-
ing the specificity of the response, and the data presented in
Figure 2 represent the lactacystin-suppressible activity. The PIF-
induced increase in chymotrypsin-like activity of the proteasome
was also attenuated by 50 mM EPA (Figure 2), which has also been
shown to attenuate protein catabolism induced by PIF in C2C12
myoblasts (Smith et al, 1999). Lower concentrations of EPA
(25mM) were ineffective. The plasma concentration of EPA in
humans consuming therapeutic levels of this fatty acid might be
expected to be in the range 100–200mM. As with protein
degradation, chymotrypsin-like activity exhibited a bell-shaped
dose–response curve. A similar effect was observed for expression
of 20S proteasome subunits as detected by Western blotting
(Figure 3A) as well as for p42, an ATPase subunit of the 19S
regulator (Figure 3C). After 24 h incubation with PIF, maximal
increase in expression was seen between 4 and 16 nM PIF with an
almost two-fold increase at 4 nM PIF (Figure 3B and D). Myotubes
treated with 50 mM EPA for 2 h prior to the addition of PIF showed
no increase in the expression of 20S a-subunits at any PIF
concentration (Figure 3), although there was no effect on
expression of p42 at the higher concentrations of PIF. These
results confirm the ability of EPA to attenuate the increased
expression of 20S proteasome subunits induced by PIF.
A time course for the effect of PIF on IkBa levels in C2C12
myotubes is shown in Figure 4A. There was a transient decrease in
cytosolic IkBa levels after 30min incubation with PIF at 4 nM, but
not at 40 nM. When analysed densitometrically, the level of IkBa
was found to decrease by 75% from the control value within 30min
of the addition of 4 nM PIF (Figure 4B). The level of IkBa returned
to normal at 60min and remained at this level indicating that the
cell had recovered. When treated with a wider concentration range
of PIF there was a decrease in IkBa levels in all myotubes treated
with all concentrations of PIF inducing protein degradation
(Figure 4C). Thus, after 30min there was a decrease of 99.9% at
2 nM PIF, 89.7% at 4 nM PIF and 87.1% at 8 nM PIF, as determined
by densitometric analysis, but no change at 20 nM PIF (Figure 4D).
Depletion of IkB from the cytosol was not seen in myotubes
pretreated with EPA, suggesting an effect of EPA in stabilising the
NFkB/IkB complex in the cytoplasm.
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Figure 2 Effect of PIF on the chymotrypsin-like enzyme activity in C2C12
myotubes in the absence (black boxes) or presence (grey boxes) of 50 mM
EPA (grey boxes). The data are expressed as mean7s.e.m. where n¼ 9
and the values represent the activity inhibited by 10mM lactacystin. The
differences from control are indicated as a, Po0.05 and b, Po0.001, while
differences in the presence of EPA are indicated as c, Po0.05 and d,
Po0.001.
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Figure 3 Western blot analysis of 20S proteasome a-subunit expression
(A) or (C) the 19S subunit, p42 in C2C12 myotubes 24 h after addition of
PIF alone at 0 nM (lane 1), 2 nM (lane 2), 4 nM (lane 3), 8 nM (lane 4), 16 nM
(lane 5) or 40 nM (lane 6) or after pretreatment with 50 mM EPA for 2 h and
subsequent treatment with PIF at 0 nM (lane 7), 2 nM (lane 8), 4 nM (lane 9),
8 nM (lane 10), 16 nM (lane 11) and 40 nM (lane 12). (B) Densitometric
analysis of the blot shown in (A), n¼ 2. (D) Densitometric analysis of the
blot shown in (C), n¼ 2. Values shown are in the absence (black boxes) or
presence (stippled boxes) of 50mM EPA. Differences from control are
shown as a, Po0.001, while differences from PIF-treated cells are shown as
b, Po0.001.
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The effect of PIF on NFkB activation and accumulation in the
nucleus was determined by EMSA. Proteolysis-inducing factor
stimulated an increased nuclear migration of NFkB at concentra-
tions between 2 and 8 nM (Figure 5A and B) but not at higher
concentrations. Only one sequence specific shift was identified by
competition assays, which may suggest stimulation of a single
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Figure 4 (A) The effect of PIF on IkBa expression in C2C12 myotubes at
30, 60 and 120min as determined by Western blotting. Lanes 1, 2 and 3
represent 0, 4 and 20 nM PIF after 30min; lanes 4–6 after 60min and lanes
7–9 after 120min. (B) Densitometric analysis of the blot shown in (A)
n¼ 2. Differences from control are shown as a, Po0.001. (C) The effect of
PIF on IkBa expression in C2C12 myotubes after 30min in the absence
(lanes 1–5) or presence (lanes 6–10) of 50mM EPA added 2 h prior to PIF.
The lanes represent the following concentrations of PIF: 1 and 6, 0 nM; 2
and 7, 2 nM; 3 and 8, 4 nM; 4 and 9, 8 nM and 5 and 10, 20 nM. (D)
Densitometric analysis of the blot shown in (C), n¼ 2. Differences from
control are shown as a, Po0.001.
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Figure 5 (A) Effect of PIF on the electrophoretic mobility of (g32P)
NFkB in C2C12 myotubes in the absence (lanes 1–5) and presence (lanes
6–10) of 50mM EPA. The following additions were made: lanes 1 and
60 nM PIF; lanes 2 and 7, 4 nM PIF; lanes 3 and 8, 8 nM PIF, lanes 4 and 9,
16 nM PIF and lanes 5 and 10, 20 nM PIF. Lane 11 contains a competitor,
that is an equal concentration of unlabelled NF-kB, while lane 12 contains a
noncompetitor, an equal concentration of an unlabelled, unrelated
oligonucleotide, usually AP2. (B) Densitometric analysis of the blot shown
in (A) Values shown are in the absence (black boxes) or presence (hatched
boxes) of 50mM EPA. The blot shown is representative of three separate
blots performed on different occasions. (C) The effect of SN50 on PIF-
induced upregulation of the chymotrypsin-like activity of the proteasome
measured after 24 h incubation. Solid boxes indicate PIF alone, hatched
boxes indicate PIFþ 18mM SN50. The SN50 was added 2 h prior to
PIF and remained in the culture medium throughout the experiment.
Sample size per treatment group n¼ 9 and the experiment was repeated
twice. Differences from control and SN50 treated cells are shown as c,
Po0.001.
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dimer pair by PIF. The specificity of the band to NF-kB was
confirmed from preliminary experiments using HeLa nuclear
extracts and myotubes exposed to endotoxin. The increased
nuclear levels of NFkB were not seen when PIF was added to
myotubes pretreated with 50 mM EPA (Figure 5A). The increased
levels of NFkB demonstrated in the nucleus in response to PIF and
the attenuation of this by EPA correspond to those concentrations
which induce both degradation of IkBa and increased proteasome
activity. The NFkB inhibitor peptide, SN50, also attenuated the
PIF-induced increase in chymotrypsin-like-enzyme activity
(Figure 5B) and reduced nuclear NF-kB in the presence of 4 nM
PIF by 80%. This suggests that NFkB may be involved in the PIF-
induced increase in proteasome expression.
DISCUSSION
In vivo studies in mice bearing a cachexia-inducing colon
adenocarcinoma (MAC16) have shown EPA to attenuate effectively
the development of host weight loss in a dose-dependent manner,
with preservation of both adipose tissue and skeletal muscle mass
(Beck et al, 1991). EPA has also been shown to stabilise body
weight in weight-losing patients with advanced pancreatic cancer
(Wigmore et al, 2000). Animals bearing the MAC16 tumour
showed a decreased protein synthesis and an increased protein
degradation in skeletal muscle, and treatment with EPA signifi-
cantly reduced protein degradation without an effect on protein
synthesis (Beck et al, 1991). This effect has been shown to occur by
downregulation of the increased expression of the regulatory
components of the ubiquitin–proteasome proteolytic pathway
seen in skeletal muscle of cachectic mice (Whitehouse et al, 2001a).
This study provides some evidence for the mechanism by which
this occurs.
Previous studies (Lorite et al, 2001; Gomes-Marcondes et al,
2002) have shown that PIF induces protein degradation in skeletal
muscle by upregulation of the ubiquitin–proteasome proteolytic
pathway. This study shows that the effect is concentration
dependent with only those concentrations between 2 and 16 nM
inducing protein breakdown. These same concentrations of PIF
increased expression of the 20S proteasome a-subunits and also
increased proteasome proteolytic activity, as determined by the
chymotrypsin-like enzyme activity, the predominant proteolytic
enzyme activity of the b-subunits. Protein degradation and
activation of the ubiquitin–proteasome pathway by PIF was
attenuated by lactacystin, showing the specificity of the response
and also by EPA, as occurs in the gastrocnemius muscle of mice
bearing the cachexia-inducing MAC16 tumour (Whitehouse et al,
2001a). In contrast, the related fatty acid docosahexaenoic acid
(DHA) has been shown to be ineffective in attenuating protein
catabolism and increased expression of the ubiquitin–proteasome
pathway (Whitehouse et al, 2001b). This shows that PIF induces
proteasome expression in myotubes through an intracellular
signalling cascade that is sensitive to EPA. Previous studies (Smith
et al, 1999) suggested that 15-hydroxyeicosatetraenoic acid (15-
HETE) acted as a signal for protein degradation induced by PIF
and that formation of 15-HETE was sensitive to EPA. The present
study provides some evidence for a role of NF-kB in skeletal
muscle proteolysis induced by PIF and other studies (unpublished
results) have also shown 15-HETE to induce increased expression
of the ubiquitin–proteasome pathway through an NF-kB-mediated
process.
NF-kB is accepted to regulate the transcription of genes involved
in immune responses, cell growth and cell death (Baeurele and
Baltimore, 1996). While in most cell types, NF-kB seems to
promote cell proliferation and protect against apoptosis, in skin it
appears to oppose proliferation (Dajee et al, 2003). Thus, NF-kB
can apparently have different functions in different cell types. The
role of proteolysis in skeletal muscle and the relationship to
expression of proteasome subunits and other key steps in the
ubiquitin–proteasome pathway are also confusing. Thus, Du et al
(2000) demonstrated that NF-kB was a repressor of C3 proteasome
subunit expression in rat L6 muscle cells. It has been previously
shown (Grune et al, 1996) that preventing the transcription of just
one subunit (C2) reduced not only the number of functioning
proteasomes, but also proteolytic activity and protein degradation.
Glucocorticoids were shown to stimulate C3 subunit expression by
opposing the suppressor action of NF-kB by antagonising the
interaction of the NF-kB protein with an NF-kB response element
in the C3 subunit promoter region. L6 myotubes that had been
heat shocked were protected from the catabolic effects of
dexamethasone, together with attenuation of the downregulation
of NF-kB (Luo et al, 2001). In sepsis, there is an early (4 h)
upregulation of NF-kB activity in skeletal muscle, followed by
inhibited NF-kB at 16 h (Penner et al, 2001). The latter effect
was probably due to glucocorticoids since the glucocorticoid
receptor antagonist RU38486 increased NF-kB. Incubation of L6
cells with a mixture of cytokines, including TNFa, decreased C3
proteasome subunit expression and increased the amount of
activated NF-kB.
However, other studies suggest a positive correlation bet-
ween activation of NF-kB and expression of genes of
the ubiquitin–proteasome proteolytic pathway. Li et al (1998)
showed that differentiated murine myotubes treated with
tumour necrosis factor a (TNFa) lost total protein and adult
myosin heavy chain, together with activation of NF-kB. They
showed that the activity of NF-kB could be correlated to an
increased ubiquitin conjugation to muscle proteins, and a
subsequent rise in ubiquitin mRNA, suggesting that NF-kB might
function to increase expression of members of the ubiquitin–
proteasome pathway in skeletal muscle. This conclusion was
endorsed by studies using C2C12 myotubes transfected with viral
plasmid constructs that overexpress mutant IkBa proteins that are
insensitive to degradation by the ubiquitin–proteasome pathway
(Li and Read, 2000). Total protein content and myosin heavy-chain
levels were found to be unaltered in response to TNFa, suggesting
that NF-kB is an essential mediator of TNFa-induced protein
catabolism in differentiated muscle cells. It is possible that this
apparent disparity among the literature may reflect cell-system
specific recruitment of NF-kB subunits, which may have different
biological effects. Indeed, it has already been suggested that NF-kB
may be an intermediate in both catabolic and anabolic pathways
(Mitch and Price, 2001).
The present study provides some support to the work of Li and
Read (2000) that NF-kB provides a positive signal for protein
degradation in skeletal muscle and may act to increase expression
of proteasome subunits and ubiquitin-dependent proteolysis in
murine myotubes. Certainly, nuclear accumulation of NF-kB is
increased by PIF at the same concentrations that induce protein
catabolism and upregulation of 20S proteasome a-subunit expres-
sion and this is accompanied by the disappearance of IkBa from
the cytosol. In addition, the NF-kB inhibitor peptide, SN50, which
competes for the nuclear translocation sequences of NF-kB,
attenuated both the increased DNA binding of NF-kB induced by
PIF and the increased proteasome chymotrypsin-like enzyme
activity. Both proteasome expression and nuclear accumulation of
NF-kB induced by PIF were also attenuated by EPA, which acted to
prevent the degradation of IkBa, possibly by stabilising the NF-kB/
IkB complex directly. EPA may exert its effects upon the inhibition
of IkBa degradation through interference with upstream effectors,
like IkB kinase kinase (IKK), possibly by direct binding via a
thioester or O-ester linkage as occurs in platelets (Muszbeck and
Laposata, 1993). Alternatively, the effect may be mediated through
inhibition of 15-HETE production (Smith et al, 1999), since we
have shown 15-HETE to also increase NF-kB nuclear binding and
IkBa degradation at the same concentrations that cause an
increase in protein degradation (unpublished results). It is possible
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that 15-HETE could result in the generation of reactive oxygen
species, which might regulate the redox-sensitive NF-kB (Bonizzi
et al, 1996; Li et al, 1998), possibly through oxidation of
constituent proteins that augment, or promote the release from
or degradation of IkB.
Although the present study does not confirm a role for NF-kB in
ubiquitin–proteasome proteolysis, it does suggest that NF-kB is
activated prior to the induction of this pathway by PIF. Further
studies are in progress to establish the role of NF-kB in
proteasome proteolysis.
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